RESUMEN
The variability of larval excretion impedes the parasitological diagnosis of Strongyloides stercoralis in infected individuals. We assessed the number of larvae excreted per gram (LPG) stool in 219 samples from 38 infected individuals over 7 consecutive days before and in 470 samples from 44 persons for 21 consecutive days after ivermectin treatment (200 µg kg-1 BW). The diagnostic sensitivity of a single stool sample was about 75% for individuals with low-intensity infections (⩽1 LPG) and increased to 95% for those with high-intensity infections (⩾10 LPG). Doubling the number of samples examined per person increased sensitivity to more than 95%, even for low-intensity infections. There was no indication of a cyclic excretion of larvae. After treatment, all individuals stopped excreting larvae within 3 days. Larvae were not detected during any of the following 18 days (total 388 Baermann and 388 Koga Agar tests). Two stool samples, collected on consecutive days, are recommended in settings where low or heterogeneous infection intensities are likely. In this way, taking into account the possible biological variability in excretion, the efficacy of ivermectin treatment can be assessed as soon as 4 days after treatment.
Asunto(s)
Antiparasitarios/uso terapéutico , Heces/parasitología , Ivermectina/uso terapéutico , Strongyloides stercoralis , Estrongiloidiasis/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Niño , Preescolar , Femenino , Humanos , Larva , Masculino , Persona de Mediana Edad , Estrongiloidiasis/parasitología , Adulto JovenRESUMEN
BACKGROUND: The widening gap between the numbers of patients on the waiting list for organ transplantation and the insufficient numbers of organ donors results in the use of "critical" donors, so-called marginal donors or extended criteria donors. Data concerning the evaluation of extended criteria donors (ECD) in Switzerland are sparse. METHODS: All organ donors in Switzerland between 1.1.1998 and 30.6.2009 have been evaluated for special criteria. ECD were defined on the basis of at least one of seven criteria: six DOPKI criteria (ECD-DOPKI) and/or age ≥60 yr (ECD-Age). Once included in the study, special features, short time follow-up (first 7 days after transplantation) and the cold ischaemia time of all the transplanted organs were evaluated. RESULTS: During the period 1.1.1998 to 30.6.2009, a total of 408 organ donors were classified as ECD, reflecting 39% of all organ donors in this time period. Despite the fact that all organ donors in this study fulfilled at least one inclusion criterion, the number of recipients with satisfactory primary organ function was always higher than the respective number with a negative primary outcome within the first seven days after transplantation. A longer cold ischaemia time was associated with organs showing insufficient primary organ function compared to organs with satisfactory primary function. A relevant causal relationship cannot be investigated on the basis of our limited data. In addition, a longer observation period would be necessary to draw a more precise conclusion. CONCLUSIONS: ECD as defined by DOPKI and/or age represent a high proportion of all organ donors in Switzerland but show a remarkably good outcome.
Asunto(s)
Selección de Donante/normas , Trasplante de Órganos/fisiología , Trasplante de Órganos/normas , Donantes de Tejidos/estadística & datos numéricos , Trasplantes/normas , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Isquemia Fría/efectos adversos , Selección de Donante/estadística & datos numéricos , Femenino , Supervivencia de Injerto/fisiología , Humanos , Lactante , Masculino , Persona de Mediana Edad , Trasplante de Órganos/mortalidad , Estudios Retrospectivos , Suiza , Donantes de Tejidos/clasificación , Donantes de Tejidos/provisión & distribución , Trasplantes/provisión & distribución , Adulto JovenRESUMEN
IgA nephropathy, one of the most frequent forms of glomerulonephritis, characterized by mesangial hypercellularity and glomerular extracellular matrix (ECM) expansion, often leads to end-stage renal disease over a prolonged period. We investigated whether antiproliferative treatment in a single low dose specifically targeted to the glomerular mesangium by immunoliposomes (ILs) results in an amelioration of mesangial proliferative glomerulonephritis in rats (anti-Thy1.1 nephritis). Mycophenolate mofetil (MMF) containing ILs was generated that targets the Thy1.1 antigen (OX-7) in rat mesangial cells. Treatment benefit of a single intravenous dose of these ILs given 2 days after disease induction was investigated by stereology, immunohistochemistry, and functional analyses (creatinine, albuminuria) until day +9 and was compared among untreated and free MMF-treated rats using six male Wistar rats per group. MMF-loaded OX7-IL prevented creatinine increase and albuminuria. Stereological analyses of MMF OX7-IL-treated animals yielded 30% reduction of mesangial cells on day +9 and a 40% reduction of glomerular ECM volume on day +5, compared with all of the other nephritic animals. Furthermore, at days +5 and +9 we observed decreased ECM content and decreased glomerular volume (day +5) in the MMF-OX7-IL-treated group compared with the nephritic group treated with free MMF. In conclusion, MMF-OX7-IL-based directed drug delivery represents a novel approach for treating mesangial cell-mediated forms of glomerulonephritis.
Asunto(s)
Glomerulonefritis Membranoproliferativa/tratamiento farmacológico , Inmunosupresores/farmacología , Ácido Micofenólico/análogos & derivados , Actinas/metabolismo , Animales , Apoptosis/efectos de los fármacos , Biotinilación , Colorantes , Portadores de Fármacos , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/ultraestructura , Glomerulonefritis Membranoproliferativa/inducido químicamente , Glomerulonefritis Membranoproliferativa/patología , Fragmentos Fab de Inmunoglobulinas/química , Inmunohistoquímica , Inmunosupresores/administración & dosificación , Riñón/patología , Pruebas de Función Renal , Liposomas/administración & dosificación , Liposomas/farmacología , Masculino , Metacrilatos , Microscopía Electrónica , Ácido Micofenólico/administración & dosificación , Ácido Micofenólico/farmacología , Adhesión en Parafina , Polietilenglicoles , Antígeno Nuclear de Célula en Proliferación/metabolismo , Ratas , Ratas Wistar , Antígenos Thy-1 , Adhesión del Tejido , Cloruro de TolonioRESUMEN
Definition of acute renal allograft rejection (AR) markers remains clinically relevant. Features of T-cell-mediated AR are tubulointerstitial and vascular inflammation associated with excessive extracellular matrix (ECM) remodeling, regulated by metzincins, including matrix metalloproteases (MMP). Our study focused on expression of metzincins (METS), and metzincins and related genes (MARGS) in renal allograft biopsies using four independent microarray data sets. Our own cases included normal histology (N, n = 20), borderline changes (BL, n = 4), AR (n = 10) and AR + IF/TA (n = 7). MARGS enriched in all data sets were further examined on mRNA and/or protein level in additional patients. METS and MARGS differentiated AR from BL, AR + IF/TA and N in a principal component analysis. Their expression changes correlated to Banff t- and i-scores. Two AR classifiers, based on METS (including MMP7, TIMP1), or on MARGS were established in our own and validated in the three additional data sets. Thirteen MARGS were significantly enriched in AR patients of all data sets comprising MMP7, -9, TIMP1, -2, thrombospondin2 (THBS2) and fibrillin1. RT-PCR using microdissected glomeruli/tubuli confirmed MMP7, -9 and THBS2 microarray results; immunohistochemistry showed augmentation of MMP2, -9 and TIMP1 in AR. TIMP1 and THBS2 were enriched in AR patient serum. Therefore, differentially expressed METS and MARGS especially TIMP1, MMP7/-9 represent potential molecular AR markers.
Asunto(s)
Trasplante de Riñón/patología , Riñón/patología , Adulto , Biomarcadores , Matriz Extracelular/patología , Femenino , Genes , Rechazo de Injerto/metabolismo , Rechazo de Injerto/patología , Humanos , Inmunohistoquímica , Masculino , Metaloproteinasa 2 de la Matriz , Metaloproteinasa 7 de la Matriz , Persona de Mediana Edad , ARN Mensajero , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Metzincins, such as matrix metalloproteases (MMP), and extracellular matrix (ECM) proteins are differentially regulated in inflammation. We hypothesised that metzincins are also dysregulated in experimental acute cardiac allograft rejection. We investigated the Dark Agouti-to-Lewis (DA-to-Lew) rat model of acute cardiac allograft rejection. Cyclosporine (CsA) (7.5 mg/kg/d) was given from transplantation to sacrifice (day +5). At that time, mRNA levels were analysed by Affymetrix genechip and quantitative reverse transcription polymerase chain reaction (qRTPCR). MMP protein and activities were analysed by immunohistology, fluorometry, zymography and Western blots. In untreated rejected DA allografts, mRNA levels of MMP-2/-7/-9/-/12-/14, a disintegrin and metalloprotease (ADAM)-17, tissue inhibitor of metalloprotease (TIMP)-1/-3 were increased, whereas MMP-11/-16/-24 and TIMP-2/-4 were lowered compared to native DA hearts. With respect to these untreated allografts, CsA lowered mRNA levels of MMP-7, TIMP-1/-3 (TIMP-2/-4 remained relatively low) and ADAM17, but augmented mRNA levels of MMP-11/-16/-23 and of many ECM genes. Immunohistology showed increased staining of MMP-2 in acute rejection (AR). Overall MMP activity was augmented in both transplanted groups, but CsA reduced MMP-9 activity and MMP-14 production. Taken together, MMP and TIMP were upregulated during acute AR. CsA ameliorated histology of rejection but showed potential pro-fibrotic effects. Thus, MMP and TIMP may play a role in acute cardiac allograft rejection, and beneficial modification of the MMP-ECM balance requires interventions beyond CsA.
Asunto(s)
Ciclosporina/administración & dosificación , Rechazo de Injerto/metabolismo , Trasplante de Corazón/fisiología , Metaloproteinasas de la Matriz/metabolismo , Inhibidores Tisulares de Metaloproteinasas/metabolismo , Animales , Matriz Extracelular/metabolismo , Perfilación de la Expresión Génica , Trasplante de Corazón/inmunología , Modelos Animales , ARN Mensajero/análisis , Ratas , Ratas Endogámicas Lew , Ratas Endogámicas , Trasplante Homólogo , Regulación hacia Arriba/fisiologíaRESUMEN
Advanced glycation end products (AGEs) may play a role in the pathogenesis of diabetic nephropathy, by modulating extracellular matrix turnover. AGEs are known to activate specific membrane receptors, including the receptor for AGE (RAGE). In the present study, we analyzed the various receptors for AGEs expressed by human mesangial cells and we studied the effects of glycated albumin and of carboxymethyl lysine on matrix protein and remodelling enzyme synthesis. Membrane RAGE expression was confirmed by FACS analysis. Microarray methods, RT-PCR, and Northern blot analysis were used to detect and confirm specific gene induction. Zymographic analysis and ELISA were used to measure the induction of tPA and PAI-1. We show herein that cultured human mesangial cells express AGE receptor type 1, type 2 and type 3 and RAGE. AGEs (200 microg/ml) induced at least a 2-fold increase in mRNA for 10 genes involved in ECM remodelling, including tPA, PAI-1 and TIMP-3. The increase in tPA synthesis was confirmed by fibrin zymography. The stimulation of PAI-1 synthesis was confirmed by ELISA. AGEs increased PAI-1 mRNA through a signalling pathway involving reactive oxygen species, the MAP kinases ERK-1/ERK-2 and the nuclear transcription factor NF-kappaB, but not AP-1. Carboxymethyl lysine (CML, 5 microM), which is a RAGE ligand, also stimulated PAI-1 synthesis by mesangial cells. In addition, a blocking anti-RAGE antibody partially inhibited the AGE-stimulated gene expression and decreased the PAI-1 accumulation induced by AGEs and by CML. Inhibition of AGE receptors or neutralization of the protease inhibitors TIMP-3 and PAI-1 could represent an important new therapeutic strategy for diabetic nephropathy.
Asunto(s)
Proteínas de la Matriz Extracelular/genética , Productos Finales de Glicación Avanzada/farmacología , Metaloproteinasa 2 de la Matriz/genética , Células Mesangiales/efectos de los fármacos , Anticuerpos/farmacología , Northern Blotting , Células Cultivadas , Ensayo de Inmunoadsorción Enzimática , Proteínas de la Matriz Extracelular/metabolismo , Flavonoides/farmacología , Citometría de Flujo , Expresión Génica/efectos de los fármacos , Humanos , Lisina/análogos & derivados , Lisina/farmacología , Metaloproteinasa 2 de la Matriz/metabolismo , Células Mesangiales/citología , Células Mesangiales/metabolismo , Norleucina/farmacología , Análisis de Secuencia por Matrices de Oligonucleótidos , Inhibidor 1 de Activador Plasminogénico/genética , Inhibidor 1 de Activador Plasminogénico/metabolismo , Receptor para Productos Finales de Glicación Avanzada , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunología , Receptores Inmunológicos/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidor Tisular de Metaloproteinasa-3/genética , Inhibidor Tisular de Metaloproteinasa-3/metabolismo , Activador de Tejido Plasminógeno/genética , Activador de Tejido Plasminógeno/metabolismo , alfa-Macroglobulinas/genética , alfa-Macroglobulinas/metabolismoRESUMEN
Chronic renal allograft injury is often reflected by interstitial fibrosis (IF) and tubular atrophy (TA) without evidence of specific etiology. In most instances, IF/TA remains an irreversible disorder, representing a major cause of long-term allograft loss. As members of the protease family metzincins and functionally related genes are involved in fibrotic and sclerotic processes of the extracellular matrix (ECM), we hypothesized their deregulation in IF/TA. Gene expression and protein level analyses using allograft biopsies with and without Banff'05 classified IF/TA illustrated their deregulation. Expression profiles of these genes differentiated IF/TA from Banff'05 classified Normal biopsies in three independent microarray studies and demonstrated histological progression of IF/TA I to III. Significant upregulation of matrix metalloprotease-7 (MMP-7) and thrombospondin-2 (THBS-2) in IF/TA biopsies and sera was revealed in two independent patient sets. Furthermore, elevated THBS-2, osteopontin (SPP1) and beta-catenin may play regulatory roles on MMP. Our findings further suggest that deregulated ECM remodeling and possibly epithelial to mesenchymal transition (EMT) are implicated in IF/TA of kidney transplants, and that metzincins and related genes play an important role in these processes. Profiling of these genes may be used to complement IF/TA diagnosis and to disclose IF/TA progression in kidney transplant recipients.
Asunto(s)
Regulación de la Expresión Génica/genética , Trasplante de Riñón , Adulto , Atrofia/genética , Femenino , Fibrosis/genética , Perfilación de la Expresión Génica , Humanos , Inmunohistoquímica , Enfermedades Renales/genética , Enfermedades Renales/metabolismo , Enfermedades Renales/fisiopatología , Enfermedades Renales/cirugía , Trasplante de Riñón/clasificación , Masculino , Metaloproteinasa 7 de la Matriz/genética , Metaloproteinasa 7 de la Matriz/metabolismo , Persona de Mediana Edad , ARN Mensajero/genética , Trombospondinas/genética , Trasplante HomólogoRESUMEN
Long-term follow-up examination to test whether therapy with mycophenolate mofetil (MMF) or azathioprine (AZA) during the first year translates into different graft or patient survival and graft function is important. Therefore, 6-year follow-up data of a group of 80 consecutive renal transplant recipients were analyzed. The first group of 40 patients was treated with AZA, cyclosporine and prednisone and the second group with MMF, cyclosporine and prednisone for the first 6 months. Graft failure rates were compared during follow-up. Creatinine, inverse slope of creatinine (delta/creatinine) and 24-hour proteinuria at 6 years post transplantation were compared. The Kaplan-Meier analyses for death-censored and non-censored graft failure showed no difference between the groups. Creatinine values at 6 years for the AZA Group were 139 +/- 36 micromol/l (95% CI 125.9-151.2 micromol/l) and for the MMF Group 149 +/- 52 micromol/l (95% CI 133.9-164.9 micromol/l). Delta/creatinine and 24-hour proteinuria at 6 years did not differ between the two groups. We conclude that an initial 6-month treatment with MMF as opposed to AZA reduced the early rejection rate, but did not result in superior long-term graft function or survival after 6 years of follow-up observation.
Asunto(s)
Azatioprina/uso terapéutico , Trasplante de Riñón/inmunología , Ácido Micofenólico/análogos & derivados , Causas de Muerte , Estudios de Seguimiento , Rechazo de Injerto/clasificación , Rechazo de Injerto/epidemiología , Hemoglobinas/metabolismo , Humanos , Inmunosupresores/uso terapéutico , Trasplante de Riñón/mortalidad , Ácido Micofenólico/uso terapéutico , Análisis de Supervivencia , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Helmintiasis/parasitología , Parasitosis Intestinales/parasitología , Infecciones por Protozoos/parasitología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Niño , Preescolar , Eucariontes , Heces/parasitología , Femenino , Helmintiasis/diagnóstico , Helmintos , Humanos , Lactante , Recién Nacido , Parasitosis Intestinales/diagnóstico , Masculino , Microscopía/métodos , Persona de Mediana Edad , Infecciones por Protozoos/diagnósticoRESUMEN
Chronic renal allograft rejection is characterized by alterations in the extracellular matrix compartment and in the proliferation of various cell types. These features are controlled, in part by the metzincin superfamily of metallo-endopeptidases, including matrix metalloproteinases (MMPs), a disintegrin and metalloproteinase (ADAM) and meprin. Therefore, we investigated the regulation of metzincins in the established Fisher to Lewis rat kidney transplant model. Studies were performed using frozen homogenates and paraffin sections of rat kidneys at day 0 (healthy controls) and during periods of chronic rejection at day +60 and day +100 following transplantation. The messenger RNA (mRNA) expression was examined by Affymetrix Rat Expression Array 230A GeneChip and by real-time Taqman polymerase chain reaction analyses. Protein expression was studied by zymography, Western blot analyses, and immunohistology. mRNA levels of MMPs (MMP-2/-11/-12/-14), of their inhibitors (tissue inhibitors of metalloproteinase (TIMP)-1/-2), ADAM-17 and transforming growth factor (TGF)-beta1 significantly increased during chronic renal allograft rejection. MMP-2 activity and immunohistological staining were augmented accordingly. The most important mRNA elevation was observed in the case of MMP-12. As expected, Western blot analyses also demonstrated increased production of MMP-12, MMP-14, and TIMP-2 (in the latter two cases as individual proteins and as complexes). In contrast, mRNA levels of MMP-9/-24 and meprin alpha/beta had decreased. Accordingly, MMP-9 protein levels and meprin alpha/beta synthesis and activity were downregulated significantly. Members of metzincin families (MMP, ADAM, and meprin) and of TIMPs are differentially regulated in chronic renal allograft rejection. Thus, an altered pattern of metzincins may represent novel diagnostic markers and possibly may provide novel targets for future therapeutic interventions.
Asunto(s)
Regulación de la Expresión Génica , Rechazo de Injerto , Trasplante de Riñón , Metaloproteinasas de la Matriz/genética , Metaloendopeptidasas/genética , Proteínas ADAM/genética , Proteína ADAM17 , Animales , Biomarcadores , Enfermedad Crónica , Rechazo de Injerto/diagnóstico , Rechazo de Injerto/terapia , Masculino , Metaloproteinasa 2 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/genética , Análisis de Secuencia por Matrices de Oligonucleótidos , Ratas , Ratas Endogámicas F344 , Ratas Endogámicas Lew , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidor Tisular de Metaloproteinasa-2/genética , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta1 , Trasplante HomólogoRESUMEN
Pre-eclampsia occurs in 2-5% of pregnancies of healthy women. Here, we present a rare case of pre-eclampsia with overt acute heart failure, which was the primary manifestation of systemic lupus erythematosus with cardiac and renal involvement.
Asunto(s)
Insuficiencia Cardíaca/diagnóstico , Recien Nacido Prematuro , Lupus Eritematoso Sistémico/diagnóstico , Preeclampsia/diagnóstico , Resultado del Embarazo , Enfermedad Aguda , Adulto , Biopsia con Aguja , Diagnóstico Diferencial , Ecocardiografía Doppler , Femenino , Humanos , Inmunohistoquímica , Recién Nacido , Edad Materna , Paridad , Periodo Posparto , Embarazo , Medición de Riesgo , Índice de Severidad de la EnfermedadRESUMEN
Pancreas transplantation has evolved within two decades from a poorly accepted therapeutic option to a highly successful procedure in the treatment of type 1 diabetes mellitus. Combined Pancreas-kidney transplantation is usually performed, but the value of pancreas after kidney transplant recently increased dramatically. Novel surgical techniques together with very effective immunosuppression (e.g. Prograf) and CellCept) and better postoperative management offer excellent long-term graft and patient survival with full insulin independence. Pancreas transplantation (alone or simultaneous with kidney) is highly cost-effective compared to any conservative alternatives.
Asunto(s)
Diabetes Mellitus Tipo 1/cirugía , Rechazo de Injerto/prevención & control , Trasplante de Riñón/métodos , Trasplante de Páncreas/efectos adversos , Trasplante de Páncreas/métodos , Medición de Riesgo/métodos , Recolección de Tejidos y Órganos/métodos , Europa (Continente) , Rechazo de Injerto/etiología , Humanos , Trasplante de Riñón/tendencias , América del Norte , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Factores de Riesgo , Suiza , Obtención de Tejidos y Órganos/métodos , Resultado del TratamientoRESUMEN
We report on a case of a 31-year-old patient suffering from long-standing peripheral edema with severe hypoalbuminemia, but without proteinuria. Differential diagnosis, diagnostic work-up and the therapeutic options in this unusual case are discussed. The general practitioner must keep in mind a broad range of causes when seeing every-day-patients with peripheral edema, although the correct etiology can be found easily in most cases.
Asunto(s)
Edema/etiología , Hipoalbuminemia/diagnóstico , Hipoproteinemia/diagnóstico , Pierna , Linfangiectasia Intestinal/diagnóstico , Adulto , Terapia Combinada , Diagnóstico Diferencial , Edema/terapia , Medicina Familiar y Comunitaria , Estudios de Seguimiento , Humanos , Hipoalbuminemia/etiología , Hipoalbuminemia/terapia , Hipoproteinemia/etiología , Hipoproteinemia/terapia , Linfangiectasia Intestinal/complicaciones , Linfangiectasia Intestinal/terapia , Masculino , Agregado de Albúmina Marcado con Tecnecio Tc 99mRESUMEN
Entamoeba histolytica has been separated in recent years into 2 morphologically identical species: the apathogenic E. dispar and the pathogenic E. histolytica, only the latter being pathogenic. Although various laboratory techniques allow discrimination between the 2 species there is a lack of field data about the suitability of available diagnostic tests for use in epidemiological studies and few epidemiological studies using species-specific diagnosis have been performed at community level in endemic areas, especially in sub-Saharan Africa. We conducted a repeated cross-sectional study of 967 schoolchildren in central Côte d'Ivoire to compare and evaluate light microscopy, 2 different antigen detection assays, and one polymerase chain reaction (PCR) assay. Microscopy and a non-specific antigen capture Entamoeba enzyme-linked immunosorbent assay (ELISA) were used for the primary screening of all children (time t0). The prevalence of the E. histolytica/E. dispar species complex at t0 was 18.8% by single microscopical examination and 31.4% using the non-specific ELISA. Approximately 2 months after the initial screening, fresh stool specimens were collected on 2 consecutive days (t1 and t2) from (i) all the children who were positive by microscopy at t0 (n = 182) and (ii) 155 randomly selected children who were negative at the primary screening. These samples were tested with a second antigen detection ELISA specific for E. histolytica (n = 238) and with a species-specific PCR assay (n = 193). The second and third examinations (t1 and t2) revealed an additional 43 infections with the species complex E. histolytica/E. dispar, so that the cumulative microscopical prevalence for t1 and t2 was 27.7%. The overall prevalence of E. histolytica by species-specific ELISA antigen detection was low (0.83%), while the prevalence of E. dispar was 15%. When analysing only microscopically positive samples by PCR (n = 129), the ratio E. histolytica: E. dispar was very low (1:46), suggesting that the vast majority of Entamoeba infections in this area were apathogenic. Both species-specific tests performed well but the ELISA was easier to use for large-scale field screening.
Asunto(s)
Entamebiasis/parasitología , Adolescente , Animales , Antihelmínticos/uso terapéutico , Niño , Côte d'Ivoire/epidemiología , Estudios Transversales , Entamoeba , Entamoeba histolytica , Entamebiasis/tratamiento farmacológico , Entamebiasis/epidemiología , Ensayo de Inmunoadsorción Enzimática , Femenino , Giardiasis/tratamiento farmacológico , Humanos , Masculino , Metronidazol/uso terapéutico , Reacción en Cadena de la Polimerasa , Praziquantel/uso terapéutico , Prevalencia , Esquistosomiasis mansoni/tratamiento farmacológico , Especificidad de la EspecieRESUMEN
Malignant tumors may affect the kidney in a direct and in an indirect fashion. In addition, there are multiple paraneoplastic syndromes and the side effects of the tumor therapy. Therefore, clinicians may encounter a wide spectrum of disorders representing almost all aspects of kidney diseases. Importantly, practitioners taking care of patients with glomerulopathies must always consider the possibility of a co-existence of a malignancy, as highlighted by our case report.
Asunto(s)
Carcinoma de Células Renales , Enfermedades Renales/etiología , Neoplasias Renales , Síndromes Paraneoplásicos , Adulto , Anciano , Antineoplásicos/efectos adversos , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Renales/cirugía , Neoplasias del Ciego/complicaciones , Neoplasias del Ciego/diagnóstico , Neoplasias del Ciego/cirugía , Colectomía , Colonoscopía , Femenino , Humanos , Enfermedades Renales/inducido químicamente , Neoplasias Renales/diagnóstico , Neoplasias Renales/secundario , Neoplasias Renales/cirugía , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Nefrectomía , Nefrosis Lipoidea/diagnóstico , Nefrosis Lipoidea/etiología , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: Acute renal failure induced by contrast media is an important cause of hospital-acquired renal insufficiency. Preexisting renal failure and the dose of contrast media are known risk factors for the development of radiocontrast nephropathy. We performed a randomized trial to test whether radiocontrast nephropathy can be avoided by prophylactic hemodialysis immediately after the administration of contrast media in patients with impaired renal function. SUBJECTS AND METHODS: Renal function and other parameters, hemodialysis requirement, and relevant clinical events were recorded before and during the 6 days after administration of contrast media in 113 patients with a baseline serum creatinine level >200 microm/L (>2.3 mg/dL). Patients were randomly assigned to either hemodialysis (n = 55) or nonhemodialysis (n = 58) treatment after parenteral low-osmolality contrast media. RESULTS: The characteristics of the patients in the two groups were similar. Compared with baseline levels, the mean [+/- SD] serum creatinine level decreased at day 1 (277 +/- 95 microm/L), peaked at day 4 (353 +/- 126 microm/L), and returned to baseline at day 6 (327 +/- 119 microm/L, P <0.05 by analysis of variance) after administration of contrast media in the hemodialysis group, whereas in the nonhemodialysis group, no significant changes in mean serum creatinine level were observed. Eleven patients required 1 or more hemodialyses (8 in the hemodialysis group and 3 in the nonhemodialysis group, P = 0.12), 6 of whom (4 vs. 2, P = 0.44) required 3 or more hemodialyses. Clinically relevant events included pulmonary edema (1 vs. 4 patients, P = 0.36), myocardial infarction (2 vs. 2), stroke (2 vs. 0, P = 0.24), and death (1 vs. 1). CONCLUSIONS: The strategy of performing hemodialysis immediately after the administration of low-osmolality contrast media in all patients with a reduced renal function did not diminish the rate of complications, including radiocontrast nephropathy.
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/prevención & control , Medios de Contraste/efectos adversos , Fallo Renal Crónico , Diálisis Renal , Anciano , Creatinina/sangre , Femenino , Humanos , Modelos Logísticos , Masculino , Diálisis Renal/efectos adversosRESUMEN
BACKGROUND: Cyanate formed spontaneously from urea carbamoylates non-protonated amino groups of protein, irreversibly altering function, charge and structure. Carbamoylated proteins in renal tissue have not been examined hitherto. OBJECTIVES: To identify homocitrulline (epsilon-amino-carbamoyl-lysine), a result of in vivo carbamoylation by urea-derived cyanate, from patients with renal disease or in newly transplanted kidneys by immunohistochemistry. To evaluate enzymatic activity of carbamoylated and non-carbamoylated matrix metalloproteinase-2 and correlate this with renal tissue carbamoylated in vivo. DESIGN: Anti-homocitrulline antibody is specific for homocitrulline and was used to identify carbamoylation of epsilon-amino-lysine in renal biopsies from patients with elevated BUN, with isolated proteinuria, and as controls, from normal donors at time of transplantation. Enzymatic activity of matrix metalloproteinase-2 carbamoylated in vitro was evaluated. RESULTS: Homocitrulline was present in glomerular basement membrane (8/10), mesangium (8/10), tubular epithelium and cytoplasm (7/10) and Bowman's capsule (1/10) in patients with elevated BUN. The discordant patterns of glomerular and tubular localization of homocitrulline versus immune complexes indicated that the carbamoylated proteins were not a component of immune deposits but were modified proteins in renal tissue. No homocitrulline was found in transplanted kidneys (14/15) or in proteinuric patients (2/2). Enzymatic activity of both human and rat matrix metalloproteinase-2 was strongly inhibited in a dose-dependent fashion when incubated with cyanate. CONCLUSIONS: In situ carbamoylation in proteins occurred in kidneys of patients with renal dysfunction but not in normal newly transplanted kidneys. Decreased enzymatic activity of carbamoylated enzymes may alter specific renal regulatory mechanisms. Carbamoylated proteins with altered function and charge may represent a previously underestimated mechanism in renal pathophysiology.
Asunto(s)
Citrulina/análogos & derivados , Citrulina/metabolismo , Fallo Renal Crónico/metabolismo , Metaloproteinasa 2 de la Matriz/metabolismo , Aminoácidos/metabolismo , Animales , Carbamatos , Cianatos/metabolismo , Cianatos/farmacología , Progresión de la Enfermedad , Técnica del Anticuerpo Fluorescente , Humanos , Inmunohistoquímica , Fallo Renal Crónico/terapia , Trasplante de Riñón , Microscopía Fluorescente , Proteínas/metabolismo , RatasRESUMEN
Inflammation is characterized by an excess of cell proliferation often leading to fibrosis and sclerosis with subsequent loss of organ function. We hypothesized that these features may be ameliorated by induction of cell cycle arrest and apoptosis as result of therapy with matrix metalloproteinase (MMP) inhibitors. In our study, mesangial cells and experimental mesangial proliferative glomerulonephritis provided the model of inflammation. First, we investigated the effect of the MMP inhibitor BB-1101 in anti-Thy1.1 nephritis. The numbers of apoptotic glomerular cells in nephritic rats increased about 4 and 6 times as a result of BB-1101 therapy, observed 11 and 14 days after induction of disease, respectively. Subsequently, rat mesangial cells were exposed to an MMP inhibitor in vitro. Fluorescence-activated cell sorter analyses of cells exposed to RO111-3456 demonstrated a dose-dependent cell cycle arrest in the G(0)/G(1) phase associated with increased expression of statin. The cell cycle arrest was followed by apoptosis as investigated by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) biotin nick-end labeling (TUNEL) and acridine orange/ethidium bromide stainings, as well as by annexin V binding. The induction of p53, p21, and bax, but not the Fas/FasL pathway appeared to play an important pathogenetic role. In summary, MMP inhibitors induce cell cycle arrest followed by apoptosis in mesangial cells. These features help to explain the anti-inflammatory effects of these compounds, such as reduction of mesangial cell proliferation and attenuation of extracellular matrix accumulation. In conclusion, induction of cell cycle arrest with subsequent apoptosis may offer new perspectives in the therapy of inflammation even beyond kidney diseases.
Asunto(s)
Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Mesangio Glomerular/efectos de los fármacos , Inhibidores de la Metaloproteinasa de la Matriz , Inhibidores de Proteasas/farmacología , Animales , Anexina A5/metabolismo , Compuestos de Bencilo , Dexametasona/farmacología , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Mesangio Glomerular/patología , Glomerulonefritis/etiología , Masculino , Pentoxifilina/farmacología , Proteínas Proto-Oncogénicas c-myc/análisis , Ratas , Ratas Wistar , Succinatos , Proteína p53 Supresora de Tumor/análisisRESUMEN
BACKGROUND: Ischemia-reperfusion injury can lead to organ damage, such as delayed graft function in kidney transplantation. Reactive oxygen species that play a key role in this disorder may directly activate latent matrix metalloproteinases (MMP). In the kidney, little is known about the role of MMP in ischemia-reperfusion. Therefore, the aim of our study was to analyze activity/expression of MMP and to assess their functional role by the use of the MMP inhibitor BB-94 (Batimastat). METHODS: Renal ischemia was induced by left renal pedicle occlusion for 60 min, preceded by right nephrectomy. Thirty-two female Sprague-Dawley rats were analyzed: sham-operated rats (n = 8), treated sham-operated rats (n = 4), ischemic rats (n = 12), and treated ischemic rats (n = 8). Batimastat therapy (30 mg/kg body weight/day) was initiated 2 days prior to induction of ischemia. Animals were sacrificed 12 h (n = 8) and 24 h (n = 24) after ischemia for analyses of MMP activity/expression and of plasma creatinine levels. RESULTS: We found no evidence for an alteration in the activity or expression of MMP as a result of renal ischemia-reperfusion. Importantly, plasma creatinine levels significantly increased to a mean of 374 +/- 61 micromol/l in ischemic rats after 24 h, almost identical to the BB-94-treated ischemic rats (384 +/- 36 micromol/l). The creatinine levels in sham-operated rats remained within normal limits. CONCLUSION: MMP play no role during the early phase of experimental renal ischemia-reperfusion injury.